Cromos Pharma has published a white paper that gives a comprehensive overview of clinical trial landscape in the Republic of Georgia, which is becoming a very attractive location for clinical trials

In addition to lightning-fast startup times, robust enrollment and full compliance with the ICH-GCP you will also be pleasantly surprised by the high quality of the study data evidenced by 12 recent 100% NAI (No Action Indicated) reports from FDA inspections.

Please follow the link to the whitepaper that may provide some additional insight into this issue.



To arrange an introductory meeting and find out how our experience can benefit your next clinical project.